FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned

August 2, 2026 - 00:47

The Food and Drug Administration is nearing a decision on a new type of influenza vaccine developed by Moderna, one that uses the same messenger RNA platform behind the company's COVID-19 shots. If approved, it would be the first mRNA flu vaccine to reach the U.S. market, marking a major shift in how seasonal flu protection is manufactured. The ruling is expected to have wide-ranging effects on the biotech sector, which has watched the mRNA field struggle to expand beyond its initial success.

The decision comes at a politically sensitive time. Health and Human Services Secretary Robert F. Kennedy Jr. has previously voiced skepticism about mRNA technology, raising questions about whether the agency's review will be influenced by political pressure. While FDA scientists have insisted their evaluation is based solely on safety and efficacy data, the optics are hard to ignore. Moderna's vaccine targets four strains of the flu virus and has shown strong results in late-stage trials, with a notable advantage in older adults who typically respond poorly to standard shots.

Industry analysts say approval would validate the platform's versatility and open the door for rapid updates to match circulating strains. But a rejection or delay could stall years of investment and hand an edge to rival vaccine makers using more traditional methods. The FDA has not set a public deadline, but insiders suggest a ruling could come within weeks. For now, the medical community is watching closely, aware that the outcome will shape flu prevention for a generation.